Moreover, excessive ROS production has been implicated in inflammatory tissue damage, suggesting that modulation of the CD11c–DOCK2 pathway could represent a therapeutic strategy to fine−tune neutrophil oxidative responses in diseases such as acute respiratory distress syndrome, autoimmune vasculitis, or sepsis. Here, ITGAX is linked to autoimmune vasculitis.